DAMIAN PHARMA AG has a total of 23 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in Australia, Brazil and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are NERRE THERAPEUTICS LTD, AMER MOH SAMIR and PREXTON THERAPEUTICS SA.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 2 | |
#2 | Brazil | 2 | |
#3 | Canada | 2 | |
#4 | Chile | 2 | |
#5 | China | 2 | |
#6 | EPO (European Patent Office) | 2 | |
#7 | Republic of Korea | 2 | |
#8 | Singapore | 2 | |
#9 | United States | 2 | |
#10 | WIPO (World Intellectual Property Organization) | 2 | |
#11 | Israel | 1 | |
#12 | Mexico | 1 | |
#13 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Schumacher Christoph | 19 |
#2 | Steele Ronald Edward | 13 |
#3 | Fuhrer Walter | 11 |
#4 | Steele Ronald | 6 |
#5 | Christoph Schumacher | 3 |
#6 | Ronald Edward Steele | 2 |
#7 | Walter Fuhrer | 2 |
#8 | Ronald Steele | 1 |
Publication | Filing date | Title |
---|---|---|
AU2019262310A1 | R-fadrozole for use in the treatment of aldostonerism | |
MX2019004937A | Aldosterone synthase inhibitor. | |
WO2018078049A1 | Aldosterone synthase inhibitor |